Coronavirus Information for the UC San Diego Community

Our leaders are working closely with federal and state officials to ensure your ongoing safety at the university. Stay up to date with the latest developments. Learn more.

Exploring the natural piericidins as anti-renal cell carcinoma agents targeting peroxiredoxin 1

TitleExploring the natural piericidins as anti-renal cell carcinoma agents targeting peroxiredoxin 1
Publication TypeJournal Article
Year of Publication2019
AuthorsZhou X.F, Liang Z., Li K.L, Fang W., Tian Y.X, Luo X.W, Chen Y.L, Zhan Z.K, Zhang T., Liao S.R, Liu S.W, Liu Y.H, Fenical W, Tang L.
Date Published2019/08
Type of ArticleArticle
ISBN Number0022-2623
Accession NumberWOS:000480500600016
Keywordsa1; Pharmacology & Pharmacy; prdx1; Streptomyces

Anti-renal cell carcinoma (RCC) agents with new mechanisms of action are urgently needed. Twenty-seven natural products of the piericidin class, including 17 new ones, are obtained from a marine-derived Streptomyces strain, and several of them show strong inhibitory activities against ACHN renal carcinoma cells. By exploring the mechanisms of two representative natural piericidin compounds, piericidin A (PA) and glucopiericidin A (GPA), peroxiredoxin 1 (PRDX1) is detected as a potential target by transcriptome data of PA-treated ACHN cells, as well as the paired RCC tumor versus adjacent nontumor tissues. PA and GPA induce cell apoptosis through reducing the reactive oxygen species level caused by upregulated PRDX1 mRNA and protein level subsequently and exhibit potent antitumor efficacy in nude mice bearing ACHN xenografts, with increasing PRDX1 expression in tumor. The interaction between PA/GPA and PRDX1 was supported by the docking analysis and surface plasmon resonance. Moreover, the translocation of PRDX1 into the nucleus forced by PA/GPA is proposed to be a key factor for the anti-RCC procedure. Piericidins provide a novel scaffold for further development of potent anti-RCC agents, and the new action mechanism of these agents targeting PRDX1 may improve upon the limitations of existing targeted drugs for the treatment of renal cancer.

Student Publication: 
Research Topics: